knowledge -WSS

knowledge

author：hotspot 2025-10-01 04:11:32 - browse：259

ITeos Therapeutics offered the first look at clinical data for its experimental cancer antibody that works by blocking the novel — and very buzzworthy — protein target called TIGIT.

The tumor-shrinking activity of the company’s drug, called EOS-448, was minimal but still comparable to early study data from competing TIGIT-targeted drugs in development, including ones from Roche and Merck.

iTeos presented the EOS-448 Phase 1 study results at the annual meeting of the American Association for Cancer Research on Saturday.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： FDA approves RSV monoclonal antibody for infants, toddlers

leisure time

WSS

Custom gene therapy hints at new path for rare disease treatments

Jack Smith previously got search warrant for Trump's Twitter, new court docs show

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

WHO calls for emergency meeting on new China virus, as cases spread

Maui's cultural, historic landmarks damaged in the devastating wildfires

Wayne Brady comes out as pansexual: 'Free to love whomever I want'

knowledge

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Cosmetics set for new safety regulation. Why the industry is on board

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

For Cytokinetics, FDA rejection of heart drug would help, not hinder

Psychedelics group wrestles with new pharma identity

Police still searching for prisoner who escaped from NYC hospital

State Dept. review finds Biden bears some blame for Afghanistan failures

At Orexo, a ‘turning point’ for everything but digital health

Peter Hotez and the public health issue of online harassment

Drastic changes should bring profitability, startup health insurers say

Wikipedia

Cosmetics set for new safety regulation. Why the industry is on board

As digital health tech proliferates, a new institute aims to cut through hype

Why failed clinical trials don’t always spell doom for a new drug

Twitch streamer Kai Cenat speaks out for 1st time since causing mayhem with Union Square giveaway

Whistleblower: Blue Cross Blue Shield evaded $170 million in taxes

In early work, researchers turn to CRISPR to treat Alzheimer's

entertainment

leisure time

hotspot

hotspot